Rituximab 항암화학요법에 대한 약사의 환자 교육 개선 및 적용 효과
Effects of the Improved Method in Patient Education on Rituximab Chemotherapy by Pharmacists
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Rituximab is a monoclonal antibody approved for the treatment of non-Hodgkin’slymphoma. Infusion-related reactions have been reported in 50% of the patients within 1-2 hoursof starting the infusion. The patient education had been performed after the administration ofrituximab, due to heavy work-load during the morning shift at Seoul St. Mary’s Hospital. Therefore, an improvement in education method for rituximab-containing chemotherapy wasrequired. The purpose of this study was to evaluate the improved education method and theresult of the application of new method. The patients in this study were over 19 years of age, who received the first combination chemotherapy including rituximab, at Seoul St. Mary’s Hospital from May 2011 to January 2012. The patients who received the education previous to improvement were the control group (n=20),and patients who received the improved education were the study group (n=20). The improvededucation was performed on the patients before and during the rituximab administration,respectively. The contents of the education were the same before and after the improvement. In the control group, 13 patients experienced subjective side effects, and 6 of those patientsimmediately reported their conditions (6/13, 46.2%). In the study group, 9 patients out of 11immediately reported their subjective side effects (9/11, 81.8%), and this result was not statisticallysignificant (p=0.270). The points of the recognition for hypersensitivity were shown to be50.0±25.6 and 67.2±22.6 in the control and study groups, respectively, and this was significantlyhigher in the study group (p=0.031). The patient’s understanding, needs, and satisfaction fromthe education were shown to be 68.9±14.0 and 65.0±20.6 (p=0.612), 74.3±14.0 and 75.0±19.4(p=0.904), and 80.6±14.4 and 81.3±13.1 (p=0.943), in the control and study groups, respectively. The new education methods focusing on hypersensitivity to rituximab improved on the recognitionand the management of hypersensitivity reactions.
Abstract
Rituximab is a monoclonal antibody approved for the treatment of non-Hodgkin’slymphoma. Infusion-related reactions have been reported in 50% of the patients within 1-2 hoursof starting the infusion. The patient education had been performed after the administration ofrituximab, due to heavy work-load during the morning shift at Seoul St. Mary’s Hospital. Therefore, an improvement in education method for rituximab-containing chemotherapy wasrequired. The purpose of this study was to evaluate the improved education method and theresult of the application of new method. The patients in this study were over 19 years of age, who received the first combination chemotherapy including rituximab, at Seoul St. Mary’s Hospital from May 2011 to January 2012. The patients who received the education previous to improvement were the control group (n=20),and patients who received the improved education were the study group (n=20). The improvededucation was performed on the patients before and during the rituximab administration,respectively. The contents of the education were the same before and after the improvement. In the control group, 13 patients experienced subjective side effects, and 6 of those patientsimmediately reported their conditions (6/13, 46.2%). In the study group, 9 patients out of 11immediately reported their subjective side effects (9/11, 81.8%), and this result was not statisticallysignificant (p=0.270). The points of the recognition for hypersensitivity were shown to be50.0±25.6 and 67.2±22.6 in the control and study groups, respectively, and this was significantlyhigher in the study group (p=0.031). The patient’s understanding, needs, and satisfaction fromthe education were shown to be 68.9±14.0 and 65.0±20.6 (p=0.612), 74.3±14.0 and 75.0±19.4(p=0.904), and 80.6±14.4 and 81.3±13.1 (p=0.943), in the control and study groups, respectively. The new education methods focusing on hypersensitivity to rituximab improved on the recognitionand the management of hypersensitivity reactions.
참고문헌 (18)
- Wendy H.V., "Infusion reactions : diagnosis, assessment and management", Clin J Oncol Nurs, 14(2), pp.10~21 (2010)
- Heinz J.L., "Management and preparedness for infusion and hypersensitivity reactions", The Oncologist, 12, pp.601~609 (2007)
- Christine H.C., "Managing premedications and the risk for reactions to infusional monoclonal antibody therapy", The Oncologist, 3(6), pp.725~732 (2008)
- Mabthera injection, "product information", ~
- "의약품 재심사 결과에 따른 허가사항 변경 지시 알림", 맙테라, 식약청바이오의약품정책과, 5941호(2010.12.24.), ~
- Brown B.A., "Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis : a retrospective analysis of patients treated at a US centre", Drug Saf, 34(2), pp.117~123 (2011)
- Dora L, "Evaluation of the safety and feasi- bility of rapid rituximab infusion", Asia Pac J Clin Oncol, 8(1), pp.71~75 (2012)
- Mark T., "Rapid infusion of rituximab over 60min", Eur J of Haematology, 82, pp.322~325 (2009)
- "가톨릭대학교 서울성모병원 약제부 업무량 통계(2010-2011)", ~
- 강유화, "암정보교육실 이용 환자의 만족도 조사", 병원약사회지, 27(1), pp.37~45 (2010), 한국병원약사회
- 신문희, "입원한 암환자에 대한 약사의 복약지도 서비스 평가", 한국임상약학회지, 12(2), pp.76~84 (2002), 한국임상약학회
- 지정숙, "암환자의 약물요법에 대한 전반적인 이해도와 암성통증관리의 만족도 조사", 병원약사회지, 22(3), pp.1~9 (2005), 한국병원약사회
- 허재헌, "복약지도 만족도가 복약순응도에 미치는 영향 : 외래환자를 대상으로", 한국임상약학회지, 19(2), pp.110~119 (2009), 한국임상약학회
- 김수진, "천식환자에 대한 표준화된 병원약사대상 교육과 반복적인 환자대상 복약지도를 통한 성과 분석", 약 학 회 지, 54(6), pp.507~521 (2010), 대한약학회
- 김은미(Kim, Eun Mi), "항암화학요법 개별교육을 받는 암 환자의 교육이해도와 자가간호수행 정도", Asian Oncology Nursing, 10(2), pp.163~170 (2010), 대한종양간호학회
- 박호란, "구조화된 항암화학요법교육이 암환자의 간호요구도와 만족도에 미치는효과", 한국보건간호학회지, 16(2), pp.325~336 (2002)
- 유명덕, "암환자의 교육요구도와 이해도", 석사, 지역사회간호학, pp.2003
- Kimberly K, "Enhancing Pharmacist’Recommendation Process in an Internal Medicine Resident Clinic", Journal of American Pharmacists Association, 44, pp.89~93 (2004)